(Q34318080)

1 August 2017

1 reference

title

The next generation of PDE4 inhibitors (English)

1 reference

1 August 2017

Huang Z

1

1 reference

1 August 2017

Ducharme Y

series ordinal

2

1 reference

1 August 2017

Macdonald D

series ordinal

3

1 reference

1 August 2017

Robichaud A

series ordinal

4

1 reference

1 August 2017

1 August 2001

1 reference

Current Opinion in Chemical Biology

1 August 2017

1 reference

1 August 2017

5

1 reference

1 August 2017

432-438

1 reference

1 August 2017

4

1 reference

Genomic organization of the human phosphodiesterase PDE11A gene. Evolutionary relatedness with other PDEs containing GAF domains

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Phosphodiesterase isozymes: molecular targets for novel antiasthma agents

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD).

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Tailoring cAMP-signalling responses through isoform multiplicity

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Phosphodiesterase type 4 inhibitors: potential in the treatment of multiple sclerosis?

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Phosphodiesterases 4D and 7A splice variants in the response of HUVEC cells to TNF-alpha(1)

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Histamine up-regulates phosphodiesterase 4 activity and reduces prostaglandin E2-inhibitory effects in human neutrophils.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Differential changes in the expression of cyclic nucleotide phosphodiesterase isoforms in rat brains by chronic treatment with electroconvulsive shock

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Noradrenergic lesions differentially alter the expression of two subtypes of low Km cAMP-sensitive phosphodiesterase type 4 (PDE4A and PDE4B) in rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Effects of repeated antidepressant treatment of type 4A phosphodiesterase (PDE4A) in rat brain.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Short term feedback regulation of cAMP in FRTL-5 thyroid cells. Role of PDE4D3 phosphodiesterase activation.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Expression of phosphodiesterase 4D (PDE4D) is regulated by both the cyclic AMP-dependent protein kinase and mitogen-activated protein kinase signaling pathways. A potential mechanism allowing for the coordinated regulation of PDE4D activity and expr

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

ERK2 mitogen-activated protein kinase binding, phosphorylation, and regulation of the PDE4D cAMP-specific phosphodiesterases. The involvement of COOH-terminal docking sites and NH2-terminal UCR regions

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

UCR1 and UCR2 domains unique to the cAMP-specific phosphodiesterase family form a discrete module via electrostatic interactions.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Activation of the cAMP-specific phosphodiesterase PDE4D3 by phosphorylation. Identification and function of an inhibitory domain

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

The cAMP-specific phosphodiesterase PDE4D3 is regulated by phosphatidic acid binding. Consequences for cAMP signaling pathway and characterization of a phosphatidic acid binding site

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Expression of different phosphodiesterase genes in human cavernous smooth muscle

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Recombinant expression of a type IV, cAMP-specific phosphodiesterase: characterization and structure-function studies of deletion mutants.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Zinc dependent activation of cAMP-specific phosphodiesterase (PDE4A)

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Conformational difference between PDE4 apoenzyme and holoenzyme

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Comparison of recombinant human PDE4 isoforms: interaction with substrate and inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Emetic, central nervous system, and pulmonary activities of rolipram in the dog.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Hunting the emesis and efficacy targets of PDE4 inhibitors: identification of the photoaffinity probe 8-(3-azidophenyl)-6- [(4-iodo-1H-1-imidazolyl)methyl]quinoline (APIIMQ).

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: a potential treatment for asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

The effects of phosphodiesterase type 4 inhibitors on tumour necrosis factor-alpha and leukotriene B4 in a novel human whole blood assay

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Synthesis and biological evaluation of 2,5-dihydropyrazol

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

The synthesis and biological evaluation of a novel series of phthalazine PDE4 inhibitors I

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Phthalazine PDE4 inhibitors. Part 2: the synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Palladium-catalyzed cross-coupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: a novel class of potent and selective phosphodiesterase type 4D inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Chronic obstructive pulmonary disease: emerging therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Desensitization of beta2-adrenoceptor and hypersensitization to phosphodiesterase inhibitors elicited by beta2-agonists in guinea pig eosinophils

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Cyclic 3',5'-nucleotide phosphodiesterases: potential targets for anticancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

The cAMP signaling pathway as a therapeutic target in lymphoid malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Infection of CD4+ memory T cells by HIV-1 requires expression of phosphodiesterase 4.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Pivotal role of cyclic nucleoside phosphodiesterase 4 in Tat-mediated CD4+ T cell hyperactivation and HIV type 1 replication

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Inhibition of cytokine release by and cardiac effects of type IV phosphodiesterase inhibition in early, profound endotoxaemia in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Effects of rolipram on scopolamine-induced impairment of working and reference memory in the radial-arm maze tests in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Identification of inhibitor binding sites of the cAMP-specific phosphodiesterase 4.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

Identification of substrate specificity determinants in human cAMP-specific phosphodiesterase 4A by single-point mutagenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900224-6

7 January 2021

10.1016/S1367-5931(00)00224-6

Identifiers

DOI

1 reference

1 August 2017

1 reference